Omicron and S-gene target failure cases in the highest COVID-19 case rate region in Canada-December 2021.
作者信息
Li Toni, Maier Allison, Carter Megan, Guan Tianxiu Hugh
机构信息
Kingston, Frontenac, and Lennox & Addington (KFL&A) Public Health, Kingston, Ontario, Canada.
School of Medicine, Queen's University, Kingston, Ontario, Canada.
出版信息
J Med Virol. 2022 May;94(5):1784-1786. doi: 10.1002/jmv.27562. Epub 2022 Jan 12.
Abstract
摘要
相似文献
1
Omicron and S-gene target failure cases in the highest COVID-19 case rate region in Canada-December 2021.2021年12月，加拿大新冠肺炎发病率最高地区的奥密克戎毒株和S基因靶标失败病例
J Med Virol. 2022 May;94(5):1784-1786. doi: 10.1002/jmv.27562. Epub 2022 Jan 12.
2
Baseline Sequencing Surveillance of Public Clinical Testing, Hospitals, and Community Wastewater Reveals Rapid Emergence of SARS-CoV-2 Omicron Variant of Concern in Arizona, USA.美国亚利桑那州公共临床检测、医院和社区污水的基线测序监测显示，SARS-CoV-2 关注的奥密克戎变异株迅速出现。
mBio. 2023 Feb 28;14(1):e0310122. doi: 10.1128/mbio.03101-22. Epub 2023 Jan 9.
3
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
4
Enhancing epidemiological surveillance of the emergence of the SARS-CoV-2 Omicron variant using spike gene target failure data, England, 15 November to 31 December 2021.利用刺突蛋白基因目标失败数据加强对 SARS-CoV-2 奥密克戎变异株出现的流行病学监测，英格兰，2021 年 11 月 15 日至 12 月 31 日。
Euro Surveill. 2022 Mar;27(11). doi: 10.2807/1560-7917.ES.2022.27.11.2200143.
5
SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.SARS-CoV-2 B.1.1.529（奥密克戎）变异株-美国，2021 年 12 月 1 日-8 日。
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1731-1734. doi: 10.15585/mmwr.mm7050e1.
6
Clinical profile of patients infected with suspected SARS-CoV-2 Omicron variant of concern, Tamil Nadu, India, December 2021-January 2022.2021 年 12 月至 2022 年 1 月，印度泰米尔纳德邦感染疑似 SARS-CoV-2 奥密克戎关切变异株患者的临床特征。
Indian J Med Res. 2022 Jan;155(1):165-170. doi: 10.4103/ijmr.ijmr_312_22.
7
Molecular evolution of SARS-CoV-2 from December 2019 to August 2022.SARS-CoV-2 的分子进化：2019 年 12 月至 2022 年 8 月。
J Med Virol. 2023 Jan;95(1):e28366. doi: 10.1002/jmv.28366.
8
Is Omicron the last SARS-CoV-2 Variant of Concern?奥密克戎是否是最后一个令人关注的 SARS-CoV-2 变体？
Arch Med Res. 2022 Apr;53(3):336-338. doi: 10.1016/j.arcmed.2022.01.001. Epub 2022 Jan 19.
9
Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: a comparative study in western Mexico.在墨西哥西部，比较感染野生型 SARS-CoV-2、Delta 或 Omicron 变异株的个体的症状、合并症和再感染的流行情况：一项比较研究。
Front Public Health. 2023 Apr 27;11:1149795. doi: 10.3389/fpubh.2023.1149795. eCollection 2023.
10
Rapid Shift from SARS-CoV-2 Delta to Omicron Sub-Variants within a Dynamic Southern U.S. Borderplex.在美国南部边境枢纽地区，SARS-CoV-2 的 Delta 变体迅速被 Omicron 亚变体取代。
Viruses. 2023 Feb 28;15(3):658. doi: 10.3390/v15030658.
引用本文的文献
1
Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications.从临床样本中优化 SARS-CoV-2 的培养用于临床试验申请。
mSphere. 2024 Nov 21;9(11):e0030424. doi: 10.1128/msphere.00304-24. Epub 2024 Oct 16.
2
Comparison of sinonasal symptoms in upper respiratory tract infections during the infectious diseases season of November 2023 to March 2024-a cross-sectional study.2023年11月至2024年3月传染病季节上呼吸道感染时鼻窦症状的比较——一项横断面研究
Front Med (Lausanne). 2024 Aug 29;11:1447467. doi: 10.3389/fmed.2024.1447467. eCollection 2024.
3
Challenges of SARS-CoV-2 genomic surveillance in India during low positivity rate scenario.印度在低阳性率情况下进行 SARS-CoV-2 基因组监测的挑战。
Front Public Health. 2023 Jun 27;11:1117602. doi: 10.3389/fpubh.2023.1117602. eCollection 2023.
4
Association between the overall burden of comorbidity and Ct values among the older patients with Omicron infection: Mediated by inflammation.奥密克戎感染老年患者的共病整体负担与 Ct 值的关联：炎症介导。
Front Immunol. 2023 Mar 14;14:1145044. doi: 10.3389/fimmu.2023.1145044. eCollection 2023.
5
Dynamics of SARS-CoV-2 variants characterized during different COVID-19 waves in Mali.马里不同新冠疫情浪潮期间所表征的新冠病毒变异株动态。
IJID Reg. 2023 Mar;6:24-28. doi: 10.1016/j.ijregi.2022.11.009. Epub 2022 Nov 25.
6
A model simulation on the SARS-CoV-2 Omicron variant containment in Beijing, China.中国北京针对严重急性呼吸综合征冠状病毒2奥密克戎变异株防控的模型模拟。
Intell Med. 2023 Feb;3(1):10-15. doi: 10.1016/j.imed.2022.10.005. Epub 2022 Nov 21.
7
A two-step process for in silico screening to assess the performance of qRTPCR kits against variant strains of SARS-CoV-2.两步法用于计算机筛选，以评估 qRT-PCR 试剂盒针对 SARS-CoV-2 变异株的性能。
BMC Genomics. 2022 Nov 17;23(1):755. doi: 10.1186/s12864-022-08999-3.
8
Validation of reduced S-gene target performance and failure for rapid surveillance of SARS-CoV-2 variants.用于 SARS-CoV-2 变异快速监测的 S 基因靶标性能降低和失败的验证。
PLoS One. 2022 Oct 3;17(10):e0275150. doi: 10.1371/journal.pone.0275150. eCollection 2022.
9
SARS-CoV-2 Omicron and its current known unknowns: A narrative review.SARS-CoV-2 奥密克戎及其当前已知的未知：叙述性综述。
Rev Med Virol. 2023 Jan;33(1):e2398. doi: 10.1002/rmv.2398. Epub 2022 Sep 23.
10
SARS-CoV-2 Omicron BA.5: Riding the seventh wave in Central Canada.严重急性呼吸综合征冠状病毒2型奥密克戎BA.5：加拿大中部迎来第七波疫情
Influenza Other Respir Viruses. 2022 Nov;16(6):1202-1204. doi: 10.1111/irv.13046. Epub 2022 Aug 30.
本文引用的文献
1
PCR performance in the SARS-CoV-2 Omicron variant of concern?新冠病毒奥密克戎变异株中的 PCR 性能如何？
Swiss Med Wkly. 2021 Dec 10;151:w30120. doi: 10.4414/smw.2021.w30120. eCollection 2021 Dec 6.
2
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.奥密克戎新冠病毒变体：新冠疫情的新篇章。
Lancet. 2021 Dec 11;398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6. Epub 2021 Dec 3.
Zotero 插件